Listening session with the US Food and Drug Administration, Lewy Body Dementia Association, and an expert panel

The regulatory path for drug approval is increasingly well defined. Drugs for the treatment of Alzheimer disease (AD) need to show statistically significant benefit over placebo with respect to cognitive and functional measures, with the Clinical Dementia Rating scale and Alzheimer's Disease As...

Descripción completa

Detalles Bibliográficos
Autores principales: Sabbagh, Marwan N., Taylor, Angela, Galasko, Douglas, Galvin, James E., Goldman, Jennifer G., Leverenz, James B., Poston, Kathleen L., Boeve, Bradley F., Irwin, David J., Quinn, Joseph F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983146/
https://www.ncbi.nlm.nih.gov/pubmed/36873923
http://dx.doi.org/10.1002/trc2.12375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983146/
https://www.ncbi.nlm.nih.gov/pubmed/36873923
http://dx.doi.org/10.1002/trc2.12375

Ejemplares similares